Lisdexamfetamine

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcAmphetamines for attention deficit hyperactivity disorder (ADHD) in adults
3. 2026-09-07srcEfficacy, Safety and Tolerability of Lisdexamfetamine Dimesylate Treatment Compared With Placebo in Adults With Binge-Eating Disorder: A Systematic Review and Meta-Analysis
4. 2026-09-07srcComparative pharmacology and abuse potential of oral dexamphetamine and lisdexamfetamine: A literature review
5. 2026-09-07srcMolecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review
6. 2026-09-07srcLisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
7. 2026-09-07srcOverdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.
8. 2026-09-07srcTreatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with ADHD
9. 2026-09-07srcLong-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe
10. 2026-09-07srcLisdexamfetamine: A Review in Binge Eating Disorder
11. 2026-09-07srcThe efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of ADHD in children and adults
12. 2026-09-07srcMaintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: randomized-withdrawal study design
13. 2026-09-07srcEfficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder
14. 2026-09-07srcLisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3 studies
15. 2026-09-07srcEfficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials
16. 2026-09-07srcThe neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety
17. 2026-09-07srcComparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis
18. 2026-09-07srcOverview of the treatment of binge eating disorder
19. 2026-09-07srcLisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials
20. 2026-09-07srcThe effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms
21. 2026-09-07srcHypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine
22. 2026-09-07srcRelative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder
23. 2026-09-07srcPharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder
24. 2026-09-07srcPhase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
25. 2026-09-07srcA Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
26. 2026-09-07srcA 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
27. 2026-09-07srcTrace Amines and Their Receptors
28. 2026-09-07srcLiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence
29. 2026-09-07srcRelative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution
30. 2026-09-07srcHuman pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers
31. 2026-09-07srcA randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder
32. 2026-09-07srcPharmacological properties and clinical effects of the ADHD drug, Lisdexamfetamine (Vyvanse capsules)
33. 2026-09-07srcMetabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers
34. 2026-09-07srcPharmacokinetic variability of long-acting stimulants in the treatment of children and adults with ADHD
35. 2026-09-07srcIntranasal versus oral administration of lisdexamfetamine dimesylate: pharmacokinetic study
36. 2026-09-07srcA Placebo-Controlled Trial of Lisdexamfetamine in the Treatment of Comorbid Sluggish Cognitive Tempo and Adult ADHD
37. 2026-09-07srcLisdexamfetamine — PubChem Compound CID 11597698
38. 2026-09-07srcEfficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with ADHD: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study
39. 2026-09-07srcDouble-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with ADHD
40. 2026-09-07srcAbsorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
41. 2026-09-07srcStimulant Withdrawal in a Child with Autism Spectrum Disorder and ADHD - A Case Report
42. 2026-09-07srcTramadol and amphetamine/serotonin syndrome interaction risk
43. 2026-09-07srcLisdexamfetamine legal/scheduling status across jurisdictions
44. 2026-09-07srcVyvanse (lisdexamfetamine) Pharmacokinetic Data — FDA Prescribing Information / Daily MED
45. 2026-09-07srcVyvanse (lisdexamfetamine dimesylate) FDA Approval History
46. 2026-09-07srcLisdexamfetamine chemical identifiers — SMILES, InChIKey, CAS
47. 2026-09-07srcFDA approves Vyvanse — New River Pharmaceuticals press release
48. 2026-09-04issueIssued emergency
49. 2026-09-04issueIssued info_card
50. 2026-09-04issueIssued notice
51. 2026-06-04proposal34 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
52. 2026-06-04publicationPublication — backfill
53. 2026-05-03revisionRevision 1
54. 2026-05-03genGeneration — pipeline-v5 · with 1 morepipeline-v5
55. 2026-05-03rungeneration run

The same entries, as forms: six forms.